A comprehensive examination of mental health in patients with head and neck cancer: Systematic review and meta-analysis.

Abstract

Patients with head and neck cancer (HNC) present particularly significant levels of emotional distress. However, the actual rates of clinically relevant mental health symptoms and disorders among this population remain unknown. A PRISMA/MOOSE-compliant systematic review and quantitative random-effects meta-analysis was performed to determine suicide incidence and the prevalence of depression, anxiety, distress, post-traumatic stress, and insomnia in this population. MEDLINE, WebofScience, Cochrane Central Register, KCI-Korean Journal, SciELO, Russian Science Citation Index and Ovid/PsycINFO databases were searched from database inception to August 1, 2023 (PROSPERO: CRD42023441432). Subgroup analyzes and meta-regressions were performed to investigate the effect of clinical, therapeutical, and methodological factors. 208 studies (n = 654,413, median age 60.7; 25.5% female) were identified. 19.5% patients reported depressive symptoms (95% confidence intervals [CI]=17-21%), 17.8% anxiety symptoms (95%CI = 14-21%), 34.3% distress (95%CI = 29-39%), 17.7% post-traumatic symptoms (95%CI = 6-41%) and 43.8% insomnia symptoms (95%CI = 35-52%). Diagnostic criteria assessments revealed lower prevalence of disorders: 10.3% depression (95%CI = 7-13%), 5.6% anxiety (95%CI = 2-10%), 9.6% insomnia (95%CI = 1-40%), and 1% post-traumatic stress (95%CI = 0-84.5%). Suicide pooled incidence was 161.16 per 100,000 individuals per year (95%CI = 82-239). Meta-regressions found a statistically significant higher prevalence of anxiety in patients undergoing primary chemoradiation compared to surgery, and increased distress in smokers and advanced tumor staging. European samples exhibited lower prevalence of distress. Patients with HNC presented significant prevalence of mental health concerns in all domains. Suicide remains a highly relevant concern. The prevalence of criteria-meeting disorders is significantly lower than clinically relevant symptoms. Investigating the effectiveness of targeted assessments for disorders in highly symptomatic patients is essential.